Home

Keyvisual giving

 

COMPETE.
Phase III Clinical Trial.

Phase III Clinical Trial COMPETE with n.c.a. 177Lu-Edotreotide (Solucin®) in Cancer Patients with GEP-NET compared to mTOR inhibitor Everolimus.

View details >>

ITM Radiotheranostics Satellite Symposium.

Prof M Caplin, Prof P Ruszniewski, Dr G Nicolas and Dr S Glasberg discussed about “Towards Optimizing the Application of Radiotheranostics in the Management of NET Patients” at ENETS 2019

Watch the Video >>

ITM signs long-term supply agreements with Nordic Nanovector for no-carrier-added Lutetium-177

ITM's subsidiary ITG and Nordic Nanovector have signed long-term global supply agreements for the medical radioisotope n.c.a. 177Lu / EndolucinBeta®…

Read more

Press Releases

ITM erhält Förderbescheid der Bayerischen Forschungsstiftung

Förderung des FORActinium-Projekts durch die Bayerische Forschungsstiftung zur Entwicklung eines Herstellungsverfahrens für das in der zielgerichteten…

Read more

Press Releases

ITM and Bruce Power successfully complete feasibility study

Key requirements met to start Ytterbium-176 irradiation at Bruce Power’s facilities for the production of ITM´s no-carrier-added Lutetium-177 for…

Read more

Press Releases

View all news »

Find challenging opportunities within the ITM Group. Our employees are a key success factor, as each individual contributes to the overall success of the Company through his/her work ...

Join the ITM Team >>